Melanoma is a highly aggressive skin cancer with increasing incidence worldwide. Long noncoding RNAs (lncRNAs), a group of nonprotein-coding transcripts longer than 200 nucleotides, are pervasively transcribed in the genome and are emerging as new players in tumorigenesis. The primary objective of this study was to investigate the role of six cancer-related lncRNAs in pairs of melanoma and adjacent normal tissues (ANTs). A total of 63 primary melanoma, paired ANTs, and metastatic lesions were collected in a Chinese population. Real-time PCR analysis was carried out to compare a series of cancer-related lncRNAs among primary melanoma tissues, ANTs, and metastatic lesions. In in-vitro studies, transwell migration assay was carried out to estimate the migration abilities of melanoma cells with different expression levels of urothelial carcinoma-associated 1 (UCA1) or metastasis-associated lung adenocarcinoma transcript 1 (Malat-1) lncRNAs. We found that UCA1 and Malat-1 lncRNAs were markedly more increased in melanomas than in paired ANTs (P<0.05). Melanomas at later stages (stages 3–4) showed higher expression of UCA1 lncRNA than those at early stages (stages 1–2) (P=0.455). In melanomas with lymph node metastasis, the metastatic lesions had a relatively higher expression of Malat-1 lncRNA than in paired primary tumors (P=0.414). Knockdown of UCA1 or Malat-1 lncRNA could attenuate the migrational ability of melanoma cells in in-vitro studies. Increased expression of UCA1 and Malat-1 lncRNAs might have a correlation with melanoma metastasis.
aDepartment of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Peking
bShenzhen PKU-HKUST Medical Center, Biomedical Research Institute, Guangdong, China
All supplementary digital content is available directly from the corresponding author.
Correspondence to Yanling He, MD, Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, 100020 Peking, China Tel: +86 010 85231850; fax: +86 01 085231688; e-mail: firstname.lastname@example.org and Zhengyu Fang, PhD, MD, Shenzhen-PKU-HKUST Medical Center, Biomedical Research Institute, Shenzhen, Guangdong, China Tel: +86 0755 83923333; fax: +86 0755 83920721; e-mail: email@example.com
Received December 8, 2013
Accepted March 25, 2014